Celiac disease in pediatric patients according to HLA genetic risk classes: a retrospective observational study

Carlo Tolone1, Marisa Piccirillo1, Pasquale Dolce2

  • 1Department of Pediatrics, University of Campania Luigi Vanvitelli, Naples, Italy.

Insights

This study found no direct link between HLA-DQ genotypes and clinical presentation in pediatric celiac disease (CD). However, the DQB1-02 allele may influence antibody levels and liver involvement in CD patients.

Area of Science:

  • Immunogenetics
  • Gastroenterology
  • Autoimmune Diseases

Background:

  • Celiac disease (CD) is an autoimmune disorder linked to specific HLA-DQ haplotypes.
  • Understanding the association between HLA-DQ risk and CD presentation is crucial for patient management.

Purpose of the Study:

  • To investigate the correlation between HLA-DQ risk classes and the clinical, serological, and histological manifestations of celiac disease.
  • To determine if specific HLA-DQ genotypes influence disease presentation in pediatric CD patients.

Main Methods:

  • Retrospective observational study of 300 celiac disease patients undergoing HLA typing.
  • Analysis of clinical, serological, and histological data, correlating them with HLA-DQ risk classes using statistical tests.

Main Results:

  • No significant association was found between HLA-DQ risk and overall clinical features in pediatric CD.
  • Certain HLA classes (G1, G4, G2) were associated with higher anti-tTG IgA levels (≥100 U/mL).
  • The G2 HLA class showed a higher prevalence of elevated liver enzymes, and the DQB1-02 allele may impact antibody levels and liver involvement.

Conclusions:

  • While HLA-DQ genotypes did not correlate with clinical features in this pediatric cohort, the DQB1-02 allele warrants further investigation for its potential role in antibody levels and liver involvement in celiac disease.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
53
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
476
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
62
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
53
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
84
Pedigree Analysis01:35

Pedigree Analysis

Overview
86.9K